Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 2: MICARDIS ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial Abb. 3: ONTARGET trial programme Abb. 4: ONTARGET - background Aktuelles Bild - Abb. 5: ONTARGET - background Abb. 6: ONTARGET - from HOPE to ONTARGET Abb. 7: ONTARGET - the HOPE study Abb. 8: HOPE study results: primary end point Zum letzten Bild
Abbildung 5: ONTARGET - background
Ramipril is an ACE inhibitor. It is approved for the treatment of hypertension and congestive heart failure post myocardial infarction. It is also indicated for reducing the risk of cardiovascular morbidity and mortality in patients aged >= 55 years who have clinical evidence of cardiovascular disease, stroke or peripheral vascular disease, or diabetes plus one or more additional cardiovascular risk factors. It has proven antihypertensive properties throughout the 24-h dosing interval with a once-daily dose. [4, 5] It also prolongs survival in congestive heart failure patients after myocardial infarction. [6] Both telmisartan and ramipril exert an antihypertensive effect through modulation of the renin–angiotensin system, but they act on different effectors within the system. 4. Perticone F, Pugliese F, Ceravolo R, Mattioli PL. Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Cardiology 1994;85:36-46. 5. Schreiner M, Berendes B, Verho M, Langley A, Cairns V. Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1991;18(Suppl 2):S137-S140. 6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.
 
ONTARGET - background
Vorheriges Bild Nächstes Bild   


Abbildung 5: ONTARGET - background
Ramipril is an ACE inhibitor. It is approved for the treatment of hypertension and congestive heart failure post myocardial infarction. It is also indicated for reducing the risk of cardiovascular morbidity and mortality in patients aged >= 55 years who have clinical evidence of cardiovascular disease, stroke or peripheral vascular disease, or diabetes plus one or more additional cardiovascular risk factors. It has proven antihypertensive properties throughout the 24-h dosing interval with a once-daily dose. [4, 5] It also prolongs survival in congestive heart failure patients after myocardial infarction. [6] Both telmisartan and ramipril exert an antihypertensive effect through modulation of the renin–angiotensin system, but they act on different effectors within the system. 4. Perticone F, Pugliese F, Ceravolo R, Mattioli PL. Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Cardiology 1994;85:36-46. 5. Schreiner M, Berendes B, Verho M, Langley A, Cairns V. Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1991;18(Suppl 2):S137-S140. 6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung